| 前收盘价格 | 3.66 |
| 收盘价格 | 3.61 |
| 成交量 | 4,008,000 |
| 平均成交量 (3个月) | 3,937,262 |
| 市值 | 2,723,662,592 |
| 市盈率 (P/E TTM) | 17.00 |
| 价格/销量 (P/S) | 4.82 |
| 股市价格/股市净资产 (P/B) | 2.77 |
| 52周波幅 | |
| 利润日期 | 26 Mar 2025 - 31 Mar 2025 |
| 营业毛利率 | 29.50% |
| 营业利益率 (TTM) | -0.87% |
| 稀释每股收益 (EPS TTM) | 0.220 |
| 季度收入增长率 (YOY) | -42.20% |
| 季度盈利增长率 (YOY) | -51.30% |
| 总债务/股东权益 (D/E MRQ) | 53.89% |
| 流动比率 (MRQ) | 3.45 |
| 营业现金流 (OCF TTM) | 21.08 M |
| 杠杆自由现金流 (LFCF TTM) | 7.57 M |
| 资产报酬率 (ROA TTM) | 4.82% |
| 股东权益报酬率 (ROE TTM) | 19.04% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (HK) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | HBM HOLDINGS-B | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.38 |
相关股票
| 股票 | 市值 | DY | P/E（TTM） | P/B |
|---|---|---|---|---|
| HBM HOLDINGS-B | 3 B | - | 17.00 | 2.77 |
| GENSCRIPT BIO | 23 B | - | - | 2.42 |
| OCUMENSION-B | 3 B | - | - | 1.17 |
| TOT BIOPHARM-B | 1 B | - | 190.00 | 1.70 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
|
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 20.73% |
| 机构持股比例 | 9.97% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合